A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Hydrogen peroxide (Primary)
- Indications Warts
- Focus Registrational; Therapeutic Use
- Acronyms THWART-2
- Sponsors Aclaris Therapeutics
- 25 Oct 2019 Status changed from active, no longer recruiting to completed.
- 16 Sep 2019 Primary endpoint (The primary efficacy endpoint is the proportion of subjects whose identified common warts are determined to be clear on the PWA scale (PWA=0)) has been met, according to an Aclaris Therapeutics media release.
- 16 Sep 2019 Results presented in the Aclaris Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History